TIKOMED’S ILB® restores brain energy metabolism following severe traumatic brain injury in the rat demonstrated in data published by the journal Antioxidants
Viken – 14th September 2020 – A new study on TIKOMED’s lead drug candidate, ILB®, addressing one of the underlying causes of neurodegeneration in acute and chronic diseases was published in Antioxidants today. The data from the rodent model studying severe traumatic brain injury (sTBI), showed that a single post-injury injection of ILB® has beneficial effects on the metabolic damages caused by sTBI.“This very important result of the beneficial effect of ILB® on post-impact brain metabolism was obtained using a single dose of the drug administered in a window of time compatible with clinical